A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Stopped Study SPR001-203 did not meet its primary and secondary endpoints therefore Spruce Biosciences has decided to terminate the study
Conditions
- Congenital Adrenal Hyperplasia
Interventions
- DRUG: Tildacerfont/Placebo
Sponsor
Spruce Biosciences